Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
30.70
-0.12 (-0.39%)
Oct 31, 2025, 4:00 PM EDT - Market closed
Alkermes Revenue
Alkermes had revenue of $394.19M in the quarter ending September 30, 2025, with 4.24% growth. This brings the company's revenue in the last twelve months to $1.52B, up 1.08% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.52B
Revenue Growth
+1.08%
P/S Ratio
3.31
Revenue / Employee
$845,188
Employees
1,800
Market Cap
5.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
| Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ALKS News
- 5 days ago - Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Alkermes plc Reports Third Quarter 2025 Financial Results - PRNewsWire
- 11 days ago - Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL - Business Wire
- 11 days ago - Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz - Benzinga
- 11 days ago - Alkermes plc (ALKS) M&A Call Transcript - Seeking Alpha
- 11 days ago - Alkermes to acquire Avadel for up to $2.1 billion - Reuters
- 11 days ago - Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PRNewsWire
- 13 days ago - Alkermes to Report Third Quarter Financial Results on October 28, 2025 - PRNewsWire